当前位置: 首页 >> 检索结果
62. Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
作者: Christie M Ballantyne.;Laura Gellis.;Jean-Claude Tardif.;Puja Banka.;Ann Marie Navar.;Emil Andreas Asprusten.;Russell Scott.;Erik S G Stroes.;Samar Froman.;Geraldine Mendizabal.;Fan Wang.;Alberico L Catapano.
来源: JAMA. 2025年
Persons with heterozygous familial hypercholesterolemia (HeFH) are at increased risk of atherosclerotic cardiovascular disease due to lifelong elevated levels of low-density lipoprotein cholesterol (LDL-C). Many patients with HeFH do not achieve guideline-recommended LDL-C goals with the currently available lipid-lowering therapies.
63. Familial Hypercholesterolemia Screening in Childhood and Early Adulthood: A Cost-Effectiveness Study.
作者: Brandon K Bellows.;Yiyi Zhang.;Natalia Ruiz-Negrón.;Dhruv S Kazi.;Amit V Khera.;Jessica G Woo.;Elaine M Urbina.;David R Jacobs.;Norrina B Allen.;John B Wong.;Sarah D de Ferranti.;Andrew E Moran.
来源: JAMA. 2025年
Heterozygous familial hypercholesterolemia (FH), a genetic condition, results in lifelong increased low-density lipoprotein cholesterol (LDL-C) and increases lifetime cardiovascular disease (CVD) risk. Most individuals with FH remain undiagnosed, so early FH identification and treatment could lower CVD burden.
64. Coronary Computed Tomography Angiography in Prediction of First Coronary Events.
作者: Göran Bergström.;Gunnar Engström.;Elias Björnson.;Martin Adiels.;Jonas S O Andersson.;Therese Andersson.;Carl-Johan Carlhäll.;Kerstin Cederlund.;David Erlinge.;Erika Fagman.;Elin Good.;Anders Gummesson.;Emil Hagström.;Stefan James.;Magnus Janzon.;Ioannis Katsoularis.;Jeanette Kuhl.;Henrik Löfmark.;Hanna Markstad.;Jonas Oldgren.;Viktor Oskarsson.;Ellen Ostenfeld.;Anders Persson.;Adrian Pistea.;Annika Rosengren.;Jonas Spaak.;Johan Sundström.;Stefan Söderberg.;Erik Thunström.;Carl Johan Östgren.;Lars Lind.;Tomas Jernberg.
来源: JAMA. 2025年
Risk stratification strategies in primary prevention of coronary events lack precision.
65. Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial.
作者: Christopher X Wong.;Christopher C Cheung.;Gabrielle Montenegro.;Hannah H Oo.;Isabella J Peña.;Janet J Tang.;Samuel J Tu.;Grace Wall.;Thomas A Dewland.;Joshua D Moss.;Edward P Gerstenfeld.;Zian H Tseng.;Henry H Hsia.;Randall J Lee.;Jeffrey E Olgin.;Vasanth Vedantham.;Melvin M Scheinman.;Catherine Lee.;Prashanthan Sanders.;Gregory M Marcus.
来源: JAMA. 2025年
Conventional wisdom holds that caffeinated coffee is proarrhythmic. Coffee is the most commonly consumed caffeinated beverage in the US, and a randomized trial assessing caffeinated coffee consumption in patients with atrial fibrillation (AF) has not previously been performed.
69. Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk: The TOP Randomized Clinical Trial.
作者: Panos Kougias.;Sherene E Sharath.;Min Zhan.;Jeffrey L Carson.;L Erin Norman.;Zhibao Mi.;Rupsi Pal.;Hasan Dosluoglu.;J Gregory Modrall.;George A Sarosi.;Peter Nelson.;Shipra Arya.;Alexandra Scrymgeour.;Jade Ollison.;Lawrence A Calais.;Vijay Nambi.;L Parker Gregg.;Shuaib M Abdullah.;Shirling Tsai.;Natasha Becker.;Justin C Choi.;Louisa Chiu.;Salvatore Scali.;Neal R Barshes.;Samir Awad.;Mohammed Moursi.;Matthew C Koopmann.;Mitchell Sally.;Daniel Ihnat.;Archana Ramaswamy.;Warren Gasper.;Edith Tzeng.;Mark A Wilson.;Gale Tang.;Grant Huang.;Kousick Biswas.; .
来源: JAMA. 2025年
Postoperative red blood cell transfusion guidelines recommend transfusion for hemoglobin levels less than 7 g/dL. However, the safety of this strategy in patients at high risk of cardiac events undergoing major operations remains unclear.
70. Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease: The PERMET Randomized Clinical Trial.
作者: Mary M McDermott.;Kathryn J Domanchuk.;Lu Tian.;Lihui Zhao.;Dongxue Zhang.;Lydia Bazzano.;Scott Berceli.;Michael H Criqui.;Luigi Ferrucci.;Jack M Guralnik.;Christiaan Leeuwenburgh.;Karen J Ho.;Ahmed Ismaeel.;Melina R Kibbe.;Claudia Korcarz.;Kate Kosmac.;Donald Lloyd-Jones.;Charlotte A Peterson.;James H Stein.;Robert Sufit.;John Wilkins.;Tamar S Polonsky.
来源: JAMA. 2025年
Lower extremity peripheral artery disease (PAD) is a disabling cardiovascular condition that impairs walking ability. Few effective therapies improve walking performance in people with PAD. Metformin is a widely available and inexpensive therapy for type 2 diabetes with pleiotropic effects that include activating AMP-activated protein kinase, reducing oxidative stress, and stimulating endothelial nitric oxide synthase (eNOS).
72. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.
作者: Brendon L Neuen.;Robert A Fletcher.;Stefan D Anker.;Deepak L Bhatt.;Javed Butler.;David Z I Cherney.;Kieran F Docherty.;Silvio E Inzucchi.;Meg J Jardine.;Kenneth W Mahaffey.;Finnian R McCausland.;Darren K McGuire.;John J V McMurray.;Bruce Neal.;Milton Packer.;Siddharth M Patel.;Vlado Perkovic.;Marc S Sabatine.;Rebecca J Sardell.;Scott D Solomon.;Muthiah Vaduganathan.;Christoph Wanner.;David C Wheeler.;Faiez Zannad.;Richard Haynes.;Natalie Staplin.;William G Herrington.;Hiddo J L Heerspink.; .
来源: JAMA. 2025年
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce chronic kidney disease (CKD) progression in individuals with type 2 diabetes, CKD, or heart failure. However, their effects in those with stage 4 CKD or little to no albuminuria remain uncertain.
74. Discordance in Creatinine- and Cystatin C-Based eGFR and Clinical Outcomes: A Meta-Analysis.
作者: Michelle M Estrella.;Shoshana H Ballew.;Yingying Sang.;Morgan E Grams.;Josef Coresh.;Aditya Surapaneni.;Natalia Alencar de Pinho.;Johan Ärnlöv.;Hermann Brenner.;Juan-Jesus Carrero.;Teresa K Chen.;Debbie L Cohen.;Mary Cushman.;Ron T Gansevoort.;Shih-Jen Hwang.;Lesley A Inker.;Joachim H Ix.;Keiko Kabasawa.;Tsuneo Konta.;Jennifer S Lees.;Kevan R Polkinghorne.;Michael G Shlipak.;Robin W M Vernooij.;David C Wheeler.;Ashok Kumar Yadav.;Andrew S Levey.;Kai-Uwe Eckardt.; .
来源: JAMA. 2025年
Estimated glomerular filtration rates (eGFRs) can differ according to whether creatinine or cystatin C is used for the eGFR calculation, but the prevalence and importance of these differences remain unclear.
76. Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis.
作者: Natalie Staplin.;Alistair J Roddick.;Brendon L Neuen.;Stefan D Anker.;Deepak L Bhatt.;Javed Butler.;David Z Cherney.;Kieran F Docherty.;Robert A Fletcher.;Silvio E Inzucchi.;Meg Jardine.;Kenneth W Mahaffey.;Darren K McGuire.;John J V McMurray.;Bruce Neal.;Milton Packer.;Siddharth M Patel.;Vlado Perkovic.;Marc S Sabatine.;Scott Solomon.;Muthiah Vaduganathan.;Christoph Wanner.;David C Wheeler.;Faiez Zannad.;Richard Haynes.;Hiddo J L Heerspink.;William G Herrington.; .
来源: JAMA. 2025年
There is uncertainty about the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors in participants with chronic kidney disease, with guidelines offering different strengths of recommendation based on diabetes status and urine albumin to creatinine ratio (UACR).
78. A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury: The Liberation From Acute Dialysis (LIBERATE-D) Randomized Clinical Trial.
作者: Kathleen D Liu.;Edward D Siew.;Delphine S Tuot.;Anitha Vijayan.;Gonzalo Matzumura Umemoto.;Bethany C Birkelo.;Benjamin J Lee.;Y Diana Kwong.;Ian E McCoy.;Kevin Delucchi.;Hanjing Zhuo.;Chi-Yuan Hsu.
来源: JAMA. 2025年
For patients with dialysis-requiring acute kidney injury, persistent need for dialysis is associated with increased morbidity and mortality, high health care use, and poor quality of life.
|